TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded)
Objective: The optimal timing of measurable residual disease (MRD) evaluation in acute myeloid leukemia (AML) patients has not been well defined yet. We aimed to investigate the impact of MRD in pre- and post-allogeneic hematopoietic stem cell transplantation (AHSCT) periods on prognostic parameters.